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Abstract 
Background: Bovine Leukemia Virus (BLV) is a deltaretrovirus closely related to the Human T cell leukemia virus-1 
(HTLV-1). Cattle are the natural host of BLV where it integrates into B-cells, producing a lifelong infection. Most infected 
animals remain asymptomatic but following a protracted latency period about 5 % develop an aggressive leukemia/
lymphoma, mirroring the disease trajectory of HTLV-1. The mechanisms by which these viruses provoke cellular trans-
formation remain opaque. In both viruses little or no transcription is observed from the 5′LTR in tumors, however the 
proviruses are not transcriptionally silent. In the case of BLV a cluster of RNA polymerase III transcribed microRNAs are 
highly expressed, while the HTLV-1 antisense transcript HBZ is consistently found in all tumors examined.
Results: Here, using RNA-seq, we demonstrate that the BLV provirus also constitutively expresses antisense tran-
scripts in all leukemic and asymptomatic samples examined. The first transcript (AS1) can be alternately polyade-
nylated, generating a transcript of ~600 bp (AS1-S) and a less abundant transcript of ~2200 bp (AS1-L). Alternative 
splicing creates a second transcript of ~400 bp (AS2). The coding potential of AS1-S/L is ambiguous, with a small open 
reading frame of 264 bp, however the transcripts are primarily retained in the nucleus, hinting at a lncRNA-like role. 
The AS1-L transcript overlaps the BLV microRNAs and using high throughput sequencing of RNA-ligase-mediated 
(RLM) 5′RACE, we show that the RNA-induced silencing complex (RISC) cleaves AS1-L. Furthermore, experiments 
using altered BLV proviruses with the microRNAs either deleted or inverted point to additional transcriptional interfer-
ence between the two viral RNA species.
Conclusions: The identification of novel viral antisense transcripts shows the BLV provirus to be far from silent in 
tumors. Furthermore, the consistent expression of these transcripts in both leukemic and nonmalignant clones points 
to a vital role in the life cycle of the virus and its tumorigenic potential. Additionally, the cleavage of the AS1-L tran-
script by the BLV encoded microRNAs and the transcriptional interference between the two viral RNA species suggest 
a shared role in the regulation of BLV.
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Background
The deltaretrovirus Bovine Leukemia Virus (BLV), like 
its close relative Human T-cell leukemia virus (HTLV-1), 
produces a chronic infection in its natural host (cattle and 
water buffalo), with most infected individuals remaining 
asymptomatic and about 5 % going on to develop leuke-
mia/lymphoma [1]. In humans the time between infec-
tion and the onset of Adult T cell leukemia/lymphoma 
(ATL) generally spans several decades [2], while in cat-
tle several years separate infection from progression to 
B-cell leukemia/lymphoma [3]. BLV infections are com-
mon in cattle throughout the world (with the exception 
of most European countries, the result of eradication 
programs), imposing significant economic costs on the 
livestock industry [4]. While not a natural host, it is also 
possible to experimentally infect sheep with BLV and 
in contrast to the situation in cattle, all infected sheep 
generally develop B cell leukemia/lymphoma, about 
20 months post infection [1].
BLV infects B-cells (in both cattle and sheep) and fol-
lowing an early and transient phase of horizontal repli-
cative dissemination, primarily proliferates via polyclonal 
expansion, producing many long lived clones that can be 
tracked via their proviral integration site [5]. In a sub-
set of infected individuals, for unknown reasons, one 
of these clones eventually begins to expand, producing 
an aggressive neoplasm that accumulates in the blood 
(B-cell leukemia) and/or organs (B-cell lymphoma). In 
both BLV and HTLV-1 the Tax protein has been seen as 
the principal actor in oncogenesis, especially as it is capa-
ble of driving cellular transformation [6]. However, the 
lack of Tax expression in the majority of ATLs [7] and 
BLV induced tumors [8], points to a more diverse cast 
of actors beyond Tax. In the case of HTLV-1 it has been 
evident for the last decade that the antisense product 
HTLV-1 basic leucine zipper factor (HBZ) plays a central 
role in the process of oncogenesis as it is found in 100 % 
of ATL cases examined [7, 9]. A large number of roles 
have been attributed to HBZ, with its inhibition of Tax 
mediated viral transcription postulated as a vital part of 
the viruses immune evasion strategy [7, 10]. Intriguingly, 
in addition to the protein encoded by HBZ, the HBZ 
mRNA has been implicated in supporting proliferation 
of ATL cells [11, 12]. In the case of BLV, no equivalent 
antisense transcript has been described, although it has 
recently been reported by us and others that the provi-
rus encodes a cluster of non-canonical RNA polymerase 
III transcribed microRNAs on the positive strand. These 
viral microRNAs represent ~40 % of the microRNA pool 
in transformed B cells [13, 14]. Similar to HBZ in HTLV-
1, the viral miRNAs are expressed in all BLV induced 
tumors examined to date, pointing to a vital role in the 
life cycle of the virus and cellular transformation [13].
The close relationship between BLV and HTLV-1 in 
genome organization and pathogenesis makes BLV an 
attractive model for investigating deltaretrovirus induced 
cancer. To further our understanding of the transcrip-
tional landscape of BLV infected cells and to build on our 
previous work describing small noncoding RNAs we car-
ried out high throughput RNA sequencing (RNA-seq) of 
total RNA from ovine and bovine BLV infected cells. Sur-
prisingly, we observed a large number of reads mapping 
back to the BLV genome and found that these reads were 
the products of previously unidentified BLV antisense 
transcripts originating in the BLV 3′LTR. We present evi-
dence that, like the case of HBZ, BLV antisense transcrip-
tion appears to be a consistent feature of BLV infections. 
We also find that one of the transcripts is cleaved by the 
BLV microRNAs and discuss the possible role these tran-
scripts play in the life cycle of BLV.
Results
Identification of two antisense transcripts encoded by BLV 
via deep sequencing
Previous work carried out by us and others had identi-
fied a cluster of ten microRNAs expressed from the BLV 
provirus genome utilizing a non-canonical microRNA 
biogenesis pathway involving RNA polymerase III [13, 
14]. To better understand the pattern of RNA transcrip-
tion during BLV infections we expanded our sequenc-
ing efforts beyond small RNAs and sequenced stranded 
RNA libraries produced from a variety of BLV infected 
samples. A total of 51 different samples were sequenced, 
including the BLV infected ovine B cell lines YR2 and 
L267, PBMCs from asymptomatic BLV infected sheep 
and BLV induced tumors isolated from both cattle and 
sheep. Viral transcripts and proteins originating from 
the 5′LTR are generally undetectable in tumors, the 
result of either genetic or epigenetic modifications of the 
provirus [8, 15, 16]. Stranded RNA-seq revealed a simi-
lar pattern with few sense reads observed and an absence 
of split reads corresponding to the spliced transcripts 
(Fig.  1a; Additional file  1: Table S1). The situation for 
the antisense coverage was significantly different, with 
a substantial number of antisense reads observed. Anti-
sense read coverage was concentrated at the LTRs (as 
the LTRs are identical reads originating from the 3′LTR 
will also map to the 5′LTR and vice versa) and a ~300 bp 
region just downstream of the last BLV microRNA (miR-
B5-3p). Additionally, the presence of split reads between 
base pairs 7217 and 8353 in the BLV genome pointed 
to a spliced transcript (denoted as Antisense 1, AS1). A 
second set of split reads were observed between base 
pairs 2829 and 8353, indicating the presence of a second 
transcript (denoted as Antisense 2, AS2). These puta-
tive splice sites do not overlap those found in previously 
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described sense transcripts (Fig.  1a) and splice donor/
acceptor sites matched the negative strand. PCR primers 
designed to span the putative splice sites of AS1 and AS2 
showed amplification with cDNA derived from the YR2/
L267 tumor cell lines and ovine/bovine tumors (Fig. 1b; 
Additional file 1: Fig. S1). PCR with a primer upstream 
of the BLV microRNAs and a primer in the first AS 
exon also showed amplification in YR2/L267 and the 
ovine/bovine tumors, demonstrating that the AS1 tran-
script could extend beyond the BLV microRNA region 
(AS1-L).
The number of viral antisense reads counted per mil-
lion reads (CPM) from RNA sequencing of YR2/L267 
and ovine/bovine tumors was broadly similar, ranging 
from 0.45 to 124.5 (mean = 15, median = 4.4). The CPM 
of viral sense reads ranged from 0 to 19.3 (mean =  1.7, 
median  =  0.5) (Additional file  1: Table S1). The YR2L-
TaxSN and L267LTaxSN cell lines [8], which constitutively 
express 5′LTR dependent viral transcripts and proteins, 
in addition to the RNA pol III dependent microRNAs 
had antisense CPM of 29 and 4 respectively (Additional 
file 1: Table S1), suggesting that transcription from the 5′ 
Fig. 1 Identification of antisense transcription from the BLV provirus. a Ideogram showing location of the BLV sense transcripts originating in the 
5′LTR as well as the BLV microRNAs. Below are shown the sense (red) and antisense (blue) reads mapping to the region from stranded RNA-seq of 
the L267 tumor B cell line. Based on observed antisense split reads and the results of 5′/3′RACE three BLV antisense transcripts were identified. All 
three share the same exon 1, with the 5′ end located primarily at either position 8591 or 8650. AS1-S ends as the transcript enters the BLV microRNA 
region and has a poly A tail. AS1-L extends beyond the BLV microRNA region and reads with a poly A tail can be observed at position ~5237. Finally, 
AS2 has a small exon 2 (~125 bp) and no poly A tail was observed in the majority of samples examined. b Rt-PCR using the YR2 and L267 cell lines 
and PBMCs from an uninfected sheep. Control DNA was derived from YR2. Primers used span the splice sites for AS1 and AS2. For AS1-L the reverse 
primer was upstream of the BLV microRNAs. Primers for Beta-actin (ACTB) were included as a positive control. (Rt+ reverse transcriptase positive, 
Rt− reverse transcriptase negative, base pair coordinates correspond to NCBI Accession: KT122858)
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and 3′LTRs of BLV, as well as from the RNA pol III pro-
moters, are not mutually exclusive. When compared to 
other mRNAs the antisense transcripts have relatively 
modest expression levels, with ~73 and ~76  % of host 
genes having higher expression levels than AS1 and AS2 
respectively. We also carried out RNA-seq on PBMCs 
isolated from 6 asymptomatic BLV infected sheep at 
17  months post-inoculation. The proviral load in these 
animals ranged from 5.3 to 40.6  % (mean  =  14.4  %; 
median  =  9.3  %). High throughput sequencing (HTS) 
mapping of proviral integration sites showed that in five 
of these animals the largest clone (defined by percentage 
of reads observed at each insertion point) did not exceed 
5 %. Antisense reads were detected in all 6 samples and 
at substantially higher numbers than sense reads. Addi-
tionally, the number of antisense reads mirrored the pro-
viral load (Additional file 1: Table S1). We also observed 
consistent production of BLV microRNAs in these early 
stage samples (Additional file  1: Table S1). Collectively, 
these data support the conclusion that BLV antisense 
transcription, like BLV microRNA production, is a fea-
ture of both the asymptomatic and leukemic stages of 
BLV infection.
Identification of 5′/3′ ends
To determine the 5′ and 3′ ends of both antisense tran-
scripts rapid amplification of cDNA ends (RACE) 
was completed in combination with high throughput 
sequencing. For 5′RACE, total RNA from the cell line 
YR2 was used as template and mapping of the resultant 
reads showed that 42  % of AS1 and 46  % of AS2 tran-
scripts started in U5 close to the R boundary at position 
8650 (Fig.  1). A second site (8591) within the R region 
was also frequently utilized by both AS1 (27 %) and AS2 
(21 %) (Fig. 1). Other less frequently used start sites are 
also listed (Additional file 1: Table S1).
Our approach to 3′RACE was slightly different from 
traditional methods as we used a primer in the first exon 
of AS1/2 to produce nearly full-length cDNAs, which 
were then processed into libraries for high throughput 
sequencing. Libraries were produced using total RNA 
from the cell lines YR2, L267 and FLK, three ovine and 
four bovine tumors, as well as six BLV infected sheep 
at 17  months post-inoculation. When mapped back to 
the BLV genome, the products of 3′RACE were mainly 
clustered in a region overlapping with BLV miR-B5-3p 
(Additional file 1: Fig. S2; Fig. 2). A canonical AAUAAA 
polyadenylation signal sequence (PAS) was found at 
position 6913–6918 immediately adjacent to the end of 
miR-B5-3p, however no GU rich consensus sequence was 
obvious (Fig.  2a). The observed poly A sequences were 
not confined to a single position but clustered at vari-
ous points in a ~60  bp region between 6842 and 6910. 
This region also corresponds with a position where the 
antisense read coverage drops, indicating that the major-
ity of BLV antisense transcripts utilize this poly A site, 
resulting in a short transcript (AS1-S) of approximately 
~600 bp (Fig. 1; Additional file 1: Fig. S2). In all the sam-
ples, a number of reads were observed beyond this point, 
with a second cluster of poly A sequences observed 
around position 6171. No PAS was observed adjacent to 
this position and the presence of an adenine rich region 
overlapping with the poly A sequences suggests that this 
region served as the priming site for our oligo dT primer. 
A second canonical AAUAAA (PAS) was found at posi-
tion 5257–5262 (again without an obvious GU rich con-
sensus sequence). When 3′RACE was carried out with a 
primer adjacent to this PAS and YR2 as template, reads 
were observed 20 bp upstream (Fig. 2b). Reads showing 
evidence for this poly A tail were also observed in five of 
the libraries produced using a primer extending from the 
first AS exon. An additional 3′RACE library, using YR2 
RNA as template, was sequenced on an Oxford Nanopore 
MinION. The long reads from this instrument showed a 
number of transcripts extending up to the region around 
position 5237 (Fig. 2d). The presence of a longer version 
of AS1 is also supported by PCR (Fig.  1b; Additional 
file  1: Fig. S1). Collectively these results indicate that a 
portion of the AS1 transcripts do extend into and beyond 
the BLV microRNA region, creating a long AS1 tran-
script (AS1-L). While some AS1-L transcripts appear to 
be polyadenylated at position 5237 the frequency appears 
low and in the MinION reads many of the AS1-L reads 
represent a host-viral fusion transcript, formed using 
canonical splice donor acceptor sites in the host and 
viral genomes (Fig. 2d). Additionally, it should be noted 
that the bovine tumor T1345 contains a large internal 
deletion that includes the PAS at position 5257–5262 
(includes the last ~100 bp of AS1-L, assuming poly A tail 
at position ~5237) suggesting that at least in tumors, this 
portion of the transcript is dispensable.
In the case of AS2, the majority of the samples showed 
no evidence of a poly A tail, rather the AS2 transcript 
ended abruptly at position 2704. Closer examination of 
the sequences showed the transcript had also utilized 
canonical splice donor acceptor sites in the viral and 
host genomes to form a virus-host fusion transcript. In 
each tumor examined, the sequence forming the fusion 
with AS2 corresponded to the region of the host genome 
where the provirus was inserted (Fig. 2c). In the case of 
L267, in addition to BLV-host fusion transcripts, a small 
number of AS2 reads were observed with appetent poly 
A tails (Fig. 2c). No PAS was observed in the vicinity and 
the position of the poly A varied over a ~220 bp region 
with the majority slightly upstream of the splice site uti-
lized in the formation of the BLV-host fusion transcript.
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BLV 3′LTR promoter activity and regulatory sequences 
affecting antisense transcription
The capacity of BLV to drive sense transcription from 
the 5′LTR has been investigated in detail over the years, 
however the promoter activity of the 3′LTR remained 
unexplored. To confirm that the 3′LTR was capable of 
driving expression of an antisense transcript, we inserted 
the BLV LTR upstream of a luciferase construct in both 
the 5′ and 3′ orientations (Fig. 3a). In the 3′ orientation, 
luciferase activity was significantly higher than the basal 
activity seen in the 5′ orientation (Fig.  3a). The major-
ity of regulatory motifs identified in the BLV 5′LTR are 
concentrated in the U3 region [17, 18]. Removal of the 
first 167 bp of U3 in the 3′LTR construct (3′∆) (Fig. 3a), 
Fig. 2 3′ ends of BLV antisense transcripts. Ideogram of the BLV provirus, with 3′RACE reads for L267 mapping to the BLV genome shown below. 
Potential 3′ ends of the BLV antisense transcripts are shown. a Zoomed in IGV screen shot showing a large cluster of reads with poly A tails (shown 
as T in IGV) adjacent to the end of miR-B5-3p. No signal position predominates, although the majority were located downstream (in the context of 
the AS transcript) of a canonical AAUAAA polyadenylation signal sequence (PAS). AS1 transcripts ending at this position were given the designa-
tion AS1-S. b In five of the libraries subjected to 3′RACE a small number of poly A reads were observed at position ~5237. This is located 20 bp 
downstream (in the context of the AS transcript) of a second canonical AAUAAA (PAS). Further, 3′RACE carried out on YR2 with the forward primer 
adjacent to this potential poly A site rather than the in AS1 exon 1 also showed polyadenylated products matching this position. c For AS2, only 
L267 showed any evidence of a poly A tail, however no canonical PAS was observed and no consistent poly A site was observed. In the remaining 
samples (also observed in many L267 reads) the AS2 transcript underwent splicing with the host genome. Shown are the soft clipped bases (the 
bases in the read that did not map to BLV) for YR2 mapped to the ovine genome with BLAT (http://genome.ucsc.edu/). These bases correspond 
to an exon of the ELF2 transcript ~5 kb upstream of the YR2 provirus integrated site. d Ideogram of the BLV provirus, with 3′RACE products from 
YR2 sequenced on a MinION instrument (Oxford Nanopore Technologies) and mapping to the BLV genome. Location of antisense transcripts are 
also shown. As with Illumina sequencing the majority of the reads take the form of the shorter AS1-S, some reads do extend to the postulated end 
of AS1-L at position ~5237. A number of long reads end before this position. b Mapping of the soft clipped reads with BLAT (http://genome.ucsc.
edu/) reveal that many of these transcripts are undergoing splicing with the ELF2 transcript. The large number of polymorphisms observed in the 
mapped reads are due to the high error rate observed in Nanopore reads
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Fig. 3 BLV 3′LTR antisense promoter activity and regulatory sequences affecting transcription. a Ideogram showing the three constructs used in 
luciferase assays, 5′LTR orientation, 3′LTR orientation and 3′LTR orientation with the majority of the U3 deleted (3′∆). Transcription factor binding 
sites from [24]. b Luciferase levels for the 5′LTR, 3′LTR and 3′∆ constructs. Comparison between the three constructs showed a significant differ-
ence among all three (p value <0.0001). c 5′LTR construct alone and co-transfected with a wild type (wt) Tax and transactivation deficient Tax (mut), 
which carries a E-to-K amino acid change at position 303 [39]. Tax wt caused a significant increase in luciferase levels (p value <0.0001). d Same as 
c but using the 3′LTR construct. Tax produced a significant (p value <0.001) drop in luciferase levels. e 5′LTR construct, mutation of IRF resulted in 
a modest but non significant drop in expression. Mutating DAS resulted in a statistically significant (p value <0.01) decrease (in line with previous 
reports). For 3′LTR, mutation in IRF caused modest, but non significant drop in expression, mutating DAS resulted in a significant drop (p value 
<0.0001). In the 3′∆ construct, mutating IRF and DAS caused a significant (p value <0.0001) decrease in luciferase levels (Luciferase levels are scaled 
to the left most construct in b, c and d. In E they were scaled to the appropriate wild type construct. Statistical significance was determined via 
Tukey’s multiple comparisons test, **p value <0.01; ***p value <0.001; ****p value <0.0001)
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resulted in significantly increased luciferase activity 
(Fig. 3b). As expected, expression of Tax, the potent viral 
transactivator, resulted in a dramatic increase of lucif-
erase activity with the LTR in the 5′ orientation (Fig. 3c), 
while in the 3′ orientation Tax caused a significant reduc-
tion. It has previously been reported that there is an 
Interferon Regulatory Factor (IRF) binding site in U5 
[17] and a E-Box in the R region (labeled as DAS: down-
stream activator sequence) [18]. To test if these motifs 
played a role in the 3′LTR antisense promoter activity, we 
carried out site directed mutagenesis. Disruption of the 
DAS motif caused a significant drop in luciferase activity 
for both the 5′LTR and 3′LTR constructs (Fig. 3e). In the 
case of the IRF motif, a modest although non significant 
reduction was seen in both constructs (Fig.  3e). Finally, 
disruption of the IRF and DAS motifs in the construct 
carrying the 167  bp deletion in U3 caused a significant 
reduction in luciferase activity for both motifs (Fig. 3e). 
Taken together these results show the 3′LTR is capable of 
driving antisense transcription in the BLV provirus in the 
absence of Tax and that the IRF and DAS motifs appear 
to play a role in both sense and antisense transcription.
Coding potential
Having confirmed the promoter activity of the 3′LTR and 
estimated the approximate scope of the BLV antisense 
transcripts, we next examined them for coding potential 
using the Coding Potential Assessment Tool (CPAT) [19]. 
The limited number of annotated bovine long non-cod-
ing RNAs (lncRNAs) prevented development of a robust 
bovine specific model to calculate coding probability. As 
a result, human and mouse CPAT models were utilized. 
In addition to the BLV antisense transcripts, a number of 
known BLV and HTLV-1 protein coding genes and 220 
bovine lncRNAs were analyzed. The known protein cod-
ing genes (including the HTLV-1 antisense transcript 
HBZ) were all assigned a high coding probability, while 
in contrast, >90 % of the bovine lncRNAs were assigned 
a coding probability less than 0.25 in both models (Addi-
tional file  1: Table S2). AS2 coding probability was low 
(0.003 human model, 0.022 mouse model), allowing us 
to classify it as an lncRNA. AS1-S/L were assigned an 
ambiguous coding probability of ~0.46 in the human and 
~0.39 in the mouse model, with a potential open reading 
frame (ORF) of 264 bp (shared by both AS1-S and AS1-
L). The small putative peptide sequence did not show any 
significant matches when used to search the non-redun-
dant protein sequence (nr) database with BLASTP and 
the protein families database [20].
We next examined patterns of nucleotide variation in 
the region containing the putative peptide. Using our 
RNA-seq data, we extracted the sequence of the puta-
tive AS1-S/L ORF from each of our bovine and ovine 
tumors and supplemented these with six publicly avail-
able whole genome BLV sequences from NCBI. AS1-S/L 
ORF was characterized by a nucleotide diversity (aver-
age difference per nucleotide site for all pairwise com-
parisons of available sequences) of 0.0149. In comparison 
Tax, known to be essential, had a nucleotide diversity 
of 0.0106. Throughout the putative ORF, the majority of 
the nucleotide diversity of AS1-S/L, like that of Tax, was 
concentrated in the less constrained 3rd codon position 
of the negative strand (0.034 and 0.0247 for AS1-S/L and 
Tax respectively) (Additional file  1: Fig. S3; Additional 
file 1: Table S3). It should be noted though, that for just 
over 2/3 of the sequence, the potential AS1-S/L ORF 
overlaps with parts of the R3 and G4 ORFs on the sense 
strand. Additionally, the 3rd codon position of G4 on 
the sense corresponds to the 3rd codon position of the 
potential AS1-S/L ORF on the negative strand. Neverthe-
less, this pattern of nucleotide diversity was not confined 
to the overlapping sequences and extends into the non 
overlapping region (no overlap 0.0236 vs no overlap 3rd 
0.0521; Additional file 1: Fig. S3; Additional file 1: Table 
S3). Consequently, the evidence for coding potential in 
AS1-S/L is suggestive, but not definitive, making it best 
to classify AS1-S/L as transcripts of unknown coding 
potential (TUCP) [21].
Sub‑cellular localization of BLV antisense transcripts
Given the ambiguous coding potential of the BLV anti-
sense transcripts we next sought to determine their 
location in the cell to better understand their poten-
tial functions. This was achieved by carrying out high 
throughput sequencing of total and small RNA libraries 
using cytoplasmic and nuclear enriched RNA fractions 
from the YR2 cell line. The resultant small RNA librar-
ies confirmed that the BLV microRNAs (like the cellular 
microRNAs) were enriched in the cytoplasmic fraction 
(Fig.  4). In the case of the total RNA libraries, the BLV 
antisense reads (all antisense reads were considered 
together) were enriched in the nuclear fraction (Fig.  4). 
Absolute quantification via real-time PCR using primers 
spanning the splice site of AS1-S/L and AS2 also demon-
strated that both transcripts were enriched in the nuclear 
RNA fraction (Fig. 4).
BLV microRNA guided cleavage of AS1‑L
The majority of the AS1 transcripts end adjacent to 
the end of miR-B5-3p (AS1-S), however some ~19  % 
extended beyond this point (Figs. 1, 2; Additional file 1: 
Fig. S2) and overlap the BLV microRNAs. As a result 
these AS1-L transcripts should be sliced via the action 
of RISC (RNA-induced silencing complex), with cleavage 
occurring between the 10th and 11th base pair position 
of the mature microRNA [22]. To identify the products 
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of cleavage, a modified version of RNA-ligase-mediated 
(RLM) 5′RACE [22] was employed and combined with 
high throughput sequencing. Using RNA from the YR2 
cell line, we found that ~66  % of the reads mapping to 
the ~550 bp BLV microRNA region had a 5′ end that fell 
between the 10th and 11th base pair of one of the BLV 
microRNAs. The majority of the cleavage appears to be 
driven by five of the BLV microRNAs. Of these, miR-
B1-3p was responsible for 35.7 % of the reads, miR-B2-5p 
3.4  %, miR-B2-3p 7.5  %, miR-B4-3p 16.2  % and miR-
B5-3p 2.9 % (Fig. 5; Additional file 1: Table S1). We also 
produced a library using total RNA extracted from the 
PBMCs of a sheep 19  months post-infection and found 
that ~26 % of the reads mapping to the BLV microRNA 
region showed evidence of cleavage mediated by the 
BLV microRNAs (Additional file 1: Table S1). To exam-
ine if this cleavage was occurring in the cytoplasm or 
nucleus, we produced nuclear and cytoplasmic enriched 
RNA pools from YR2 and carried out the same modi-
fied 5′RACE and sequencing. Reads showing evidence of 
cleavage mediated by the BLV microRNAs were higher 
in the cytoplasmic (~54  %) versus the nuclear fraction 
(17  %), indicating RISC mediated cleavage in the cyto-
plasm (Fig.  5; Additional file  1: Table S1). The percent-
age of reads mapping to the BLV microRNA region 
was similar within each fraction (~56  % nuclear, ~57  % 
cytoplasmic).
Altering the microRNA region in the BLV provirus reveals 
transcriptional interactions between the antisense 
transcripts and viral microRNAs
Given the observed cleavage of AS1-L in the cytoplasm 
we next sought to examine if the absence of BLV micro-
RNAs would have any effect on the relative fraction of 
AS1-S/L produced. To achieve this, we designed two 
altered BLV proviruses. In the first mutant, the BLV 
microRNAs were deleted, while in the second they were 
inverted to prevent cleavage of AS1-L (in both cases the 
PAS just upstream of BLV miR-B5-3p was also removed 
(Fig.  6a). These proviruses were transfected into HeLa 
cells, followed by 3′RACE and high throughput sequenc-
ing. Like the situation in tumors, the WT provirus 
3′RACE library showed a rapid drop off in coverage in 
the region containing the BLV microRNAs (Fig.  6a). In 
contrast, for the microRNA deleted provirus the level of 
coverage remained relatively consistent across the length 
of AS1-L, while in the inverted provirus, there was a 
gradual decrease in coverage along the length of AS1-L 
(Fig.  6a). As a result, deletion or inversion of the BLV 
microRNAs and the adjacent PAS appears to increase the 
fraction of AS1-L transcripts present.
The increased fraction of AS1-L transcripts could 
be explained in two ways. Firstly, the RNA pol III posi-
tioned at the BLV microRNAs may inhibit RNA pol II 
progression allowing the PAS adjacent to BLV miR-B5-3p 
Fig. 4 Sub-cellular localization of BLV antisense transcripts. YR2 was fractionated into cytoplasmic and nuclear enriched pools of RNA, followed by 
production of total RNA and small RNA libraries for high throughput sequencing (HTS). Read count for each library was normalised and enrich-
ment in the cytoplasm/nucleus calculated for the different classes of transcript. The HTS results were confirmed with RT-PCR using primers for the 
antisense BLV transcripts AS1 and AS2. Primers for TYR (cytoplasmic) and U6 (nuclear) were used to confirm fractionation efficacy. Both approaches 
confirm that the BLV antisense transcripts has a primarily nuclear localization (snoRNA small nucleolar RNA, snRNA small nuclear RNA)
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microRNA to mediate polyadenylation of the antisense 
transcripts, thereby forming AS1-S. By removing these 
elements, AS1-L levels increase. Secondly, by remov-
ing the microRNAs we prevent the cleavage of AS1-L in 
the cytoplasm, increasing the apparent number of AS1-L 
reads and causing their accumulation in the cytoplasm. In 
an attempt to distinguish between these two possibilities, 
we fractionated transfected cells in into nuclear and cyto-
plasm enriched RNA pools. Real-time PCR with prim-
ers spanning the splice sites for AS1-S/L, AS2 and BLV 
Fig. 5 BLV microRNA mediated cleavage of the AS1-L transcript. Shown on the X axis is the region of the BLV genome containing the BLV microR-
NAs (denoted by red rectangles). Graphed above is the percentage of high throughput sequencing reads showing evidence of cleavage at each base 
position. Libraries were prepared from total YR2 RNA and YR2 cells that were fractionated into cytoplasmic and nuclear enriched fractions. Below 
the X axis is shown the precise base pair position of cleavage for the peaks observed at miR-B1-3p and miR-B4-3p. The reference sequence is shown 
at the bottom and the individual reads above. The first 10 bp of the reads match the reference sequence, the sequence to the right of the cleavage 
point (arrow) corresponds to the RNA oligo ligated to the free 5′ end. Sites of cleavage were enriched between bp 10 and 11 of a subset of the 
mature microRNAs. The frequency of reads showing evidence of cleavage was increased in the cytoplasmic fraction. Free 5′ ends observed outside 
bp 10 and 11 of the microRNA in each sample are likely the product of RNA degradation
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sense transcripts did not show differences in the sub-cel-
lular distribution of transcripts for the three proviruses 
(Fig. 6b). As a result, it does not appear that the increased 
fraction of AS1-L transcripts observed is a consequence 
of eliminating BLV microRNA mediated slicing of AS1-L, 
rather it suggests the first scenario involving RNA pol II 
and pol III interference.
Knock down of AS1 with locked nucleic acids (LNAs)
A mix of three LNAs, targeting different parts of AS1 
were used to treat both the YR2 and L267cell lines, with a 
biological replicate for each cell line, at concentrations of 
5 and 10 μM. In addition, the cell lines were treated with 
10  μM of control LNAs and with a mock treatment of 
H2O. Dunn’s multiple comparisons test was then used to 
examine differences between the individual samples and 
found that at the 10 μM concentration, the drop (>50 %) 
between the control and AS specific LNAs was significant 
(p value =  0.0347). In the case of AS2 a significant dif-
ference was observed between the treatments (Kruskal–
Wallis test, p value =  0.0208), however Dunn’s multiple 
comparisons test failed to show any difference between 
individual samples (Additional file 1: Fig. S4A). The real 
time assay for the BLV sense transcript Tax failed to show 
amplification or was indistinguishable from the back-
ground in all the YR2 and L267 treatments (Tax express-
ing cells showed robust amplification with an average Ct 
of 21.5). As a result, it appears that knock down of AS1 
does not cause a detectable reactivation of transcription 
from the 5′LTR. Finally, there was no apparent difference 
in the viable cell counts in the treated and control cells at 
the end of the experiment (Additional file 1: Fig. S4B).
Discussion
It has been known for over a decade that BLV’s close 
relative HTLV-1 encodes an antisense transcript [10] 
and like HTLV-1, the BLV 3′LTR remains unmethylated 
in tumors [16], begging the question of a BLV antisense 
transcript. Prior to the adoption of RNA-seq, identify-
ing these transcripts required a certain amount of luck 
in the placement of primers/probes for Rt-PCR/North-
ern blotting. However, as can be seen from Fig. 1 the use 
of RNA-seq, especially in combination with stranded 
libraries, made the presence of antisense reads in BLV 
tumors obvious. The consistent pattern of antisense tran-
scription across all the BLV samples sequenced to date 
strongly suggests that these transcripts fulfill an essential 
function in the biology of BLV and leukemogenesis. Fur-
thermore, in the majority of samples little or no evidence 
of sense transcription was observed, mirroring results 
recently obtained in HTLV-1 [9]. While we saw evidence 
of antisense without sense transcription, we did not see 
the inverse. RNA-seq of YR2LTaxSN/L267LTaxSN and the 
3′RACE library from the FLK cell line showed that anti-
sense expression levels and splicing patterns were compa-
rable to that seen in ovine and bovine tumors (Additional 
file 1: Table S1; Additional file 1: Fig. S2), despite robust 
sense transcription. A related question was the temporal 
pattern of expression of the BLV antisense transcripts. By 
combining stranded RNA-seq, high-throughput mapping 
of proviral integration sites, 3′RACE and small RNA-
seq of PBMCs from asymptomatic BLV infected sheep 
(Additional file  1: Table S1) we could be confident that 
antisense/microRNA transcription is a feature of BLV 
infected B cell clones present at the polyclonal stage and 
not confined to the tumor clone. Given the tractability of 
the BLV sheep model, in comparison to the difficulty of 
studying primary HTLV-1 infections [23] it will be inter-
esting to extend this analysis back to the earliest stages 
of infection to examine the dynamics of sense, antisense 
and microRNA expression from BLV. The Tax protein has 
been seen as the primary actor in both HTLV-1 and BLV, 
however over the course of infection it is now apparent 
that its expression is the exception rather than the rule, 
while antisense transcription appears the rule. Probing 
the initial infection in experimentally infected sheep may 
elucidate if and how Tax sets the stage for tumor devel-
opment and if antisense transcription displays more 
dynamism in comparison to its consistent expression in 
both the established nonmalignant and expanded tumor 
clones.
The presence of BLV antisense transcription implies 
that the BLV LTR (like that of HTLV-1) is capable of 
driving transcription in both directions. Extensive work 
over the years has revealed a rich set of regulatory motifs 
bound by cellular transcription factors and Tax [18, 24], 
(See figure on previous page.) 
Fig. 6 Mutant proviruses altered in the microRNA region reveal interactions between the antisense transcripts and the viral microRNAs. a 
Ideograms showing the three BLV proviruses used in transfections, the first a wild-type, the second where the microRNAs were deleted (grey box 
indicates the region removed), the third where the BLV microRNAs were inverted. 3′RACE on total RNA from HeLa cells transfected with the three 
constructs shows that the microRNA deletion/inversion increases the fraction of AS1-L reads. In the case of the wild-type provirus and the micro-
RNA-deleted provirus, reads were mapped to the wild type provirus sequence. In the case of the microRNA-inverted provirus, they were mapped 
to a proviral genome with microRNAs inverted to match the provirus used. b Nuclear versus cytoplasmic enrichment for BLV sense and antisense 
transcripts obtained via real-time RT-PCR with nuclear and cytoplasmic enriched RNA from HeLa cells transfected with either the wild type BLV 
pBLV344 provirus, the provirus with the BLV microRNAs deleted or with the orientation of the BLV microRNAs inverted. Removing or inverting the 
BLV microRNAs had no effect on the localization of the sense or antisense transcripts. TYR cytoplasmic enriched control, U6 nuclear enriched control
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regulating the BLV 5′LTR. As expected given the evi-
dence of antisense transcription, we found that the BLV 
LTR was able to drive transcription in the orientation of 
the 3′LTR and with a significantly higher activity com-
pared to the weak basal activity typical of the 5′LTR. Our 
data are consistent with observations reported by Van 
Driessche et  al. [25] demonstrating RNA Pol II recruit-
ment to the 3′LTR-host boundary and its association with 
positive epigenetic marks. Removal of the majority of the 
regulatory motifs in U3, taken with the results from Tax 
co-transfection suggest that the motifs in U3 do not have 
a role in driving, but rather obstruct BLV antisense tran-
scription. In contrast, the motifs in the R and U5 regions 
appear to have a dual role in driving expression from 
both the 5′ and 3′LTRs. Taken in conjunction with our 
sequencing results it appears that consistent antisense 
expression from the 3′LTR is a feature of the BLV provi-
rus in both nonmalignant and tumor clones. In contrast, 
the 5′LTR is tightly regulated and does not show evidence 
of consistent expression. As a consequence, it is appar-
ent that Tax is not required for maintaining malignancy 
and the absence of this immuno-dominant viral protein 
in transformed cells plays a vital role in BLVs immune 
evasion strategy. In contrast, the permanent production 
of both antisense transcripts and microRNAs, besides 
pointing to an essential function in tumorigenesis, indi-
cates that these transcripts are incapable of eliciting an 
effective host immune response.
Having established the presence of BLV antisense tran-
scripts we attempted to determine their approximate 
size with a combination of short and long reads. It was 
somewhat surprising to see that the majority of AS1 is 
only ~600  bp in length, a much shorter transcript than 
HBZ (>2 kb) in HTLV-1 [7], while AS2 exon 2 was small 
(~125  bp) and generally forms fusion transcripts with 
the host genome. Our 3′RACE and long read sequenc-
ing showed that the longer version of the AS1 transcript 
(AS1-L > 2 kb) could extend to a poly A tail just beyond 
the canonical AAUAAA (PAS) at 5257–5262. How-
ever the balance between the use of this poly A tail and 
the formation of fusions with the host genome remains 
unknown and will likely depend on the location of the 
provirus in the genome. The use of long read technologies 
such as the MinION will be particularly useful in answer-
ing this question, as full-length sequences can unambigu-
ously determine the structure of fusion transcripts.
RNA-seq data indicated that the majority of the AS1 
reads take the form of the AS1-S variant, which termi-
nates next to the end of miR-B5-3p and is considerably 
smaller than HBZ. In the case of the AS1-L, there is an 
overlap with the BLV microRNAs leading to the cleavage 
of AS1-L via action of the RISC complex [26]. Our modi-
fied 5′RACE experiments confirmed this and showed 
that RISC mediated cleavage predominated in the cyto-
plasm (the fraction also enriched for BLV microRNAs 
in YR2). The limited number of microRNAs involved in 
cleavage is intriguing as previous work indicates that all 
the BLV microRNAs tested associate with the RISC com-
plex [13]. This may point to secondary structures in BLV 
AS1-L that inhibit cutting at certain positions, however 
the significance of this observation remains to be deter-
mined and more samples are required to see if this pat-
tern is consistent. Another question requiring future 
work is the fraction of reads that are subjected to cleav-
age. The majority of the AS1 transcripts (AS1-S) do not 
contain the region complementary to the BLV microR-
NAs. Additionally, a majority of the antisense transcripts 
are retained in the nucleus while the BLV microRNAs are 
predominantly found in the cytoplasm. How the nuclear 
versus cytoplasmic localization of AS1-L and the balance 
between AS1-S versus AS1-L evolves over the entire life 
cycle of the virus, in different cell types and in times of 
cellular stress remains an open question. Exploring these 
dynamics could be important to understand the signifi-
cance of microRNA mediated cleavage of AS1-L.
Other microRNA producing viruses such as SV40 [27] 
and Epstein–Barr virus [28] possess viral microRNAs 
that cleave products from the complementary strand. 
It is thought that this microRNA mediated regulation 
manages the transition from latency (low stress) to the 
lytic stage (high stress). With stress mediated suppres-
sion of microRNA production, cleavage of the antisense 
product is relaxed, allowing it to signal activation of the 
latent virus [29]. It is conceivable that a similar mecha-
nism is involved in regulating the relative abundance of 
the BLV AS1-S/L transcripts as RNA pol III transcription 
is known to be regulated by cell stress and cell cycle stage 
[30]. In addition to reducing the amount of microRNAs 
available for cleaving the AS1-L, changes in RNA pol III 
promoter occupancy and transcription could increase 
the fraction of AS1-L produced by removing RNA pol III 
complexes on the sense strand potentially impeding RNA 
Pol II and encouraging production of the larger transcript 
(AS1-L). It is apparent in Fig. 1 and Additional file 1: Fig. 
S2 that antisense coverage diminishes as we enter the 
region containing the BLV microRNAs. RACE experi-
ments with RNA from HeLa transfections showed that 
deleting/inverting the microRNAs/PAS in the BLV pro-
virus results in a higher fraction of AS1-L (Fig. 6a) with-
out altering the fraction of AS transcripts localized in the 
nucleus or cytoplasm. This suggests the removal of an 
insulator that prevents progression of RNA pol II rather 
than reduced microRNA mediated cleavage of AS1-L. 
Our data are in agreement with recent Chip-seq work by 
Van Driessche et al. [25] showing evidence of a high RNA 
pol III occupancy peak in the BLV microRNA region with 
Page 13 of 16Durkin et al. Retrovirology  (2016) 13:33 
a large RNA pol II occupancy peak just downstream of 
this position, consistent with RNA pol III–RNA pol II 
collision.
The significant size difference between AS1-S and 
AS1-L is intriguing as both contain the same potential 
ORF. Assuming that the ORF does produce a functional 
protein, its potential role remains opaque as database 
searches did not reveal any significant homology with 
known protein domains. In HTLV-1, a number of roles 
have been assigned to the HBZ protein, including the 
suppression of HTLV-1 5′LTR transcription and repres-
sion of the host immune response [7]. In HTLV-2 the 
antisense protein APH-2 also plays a role in suppress-
ing viral transcription [31]. However, the potential pro-
tein in BLV AS1-S/L (87 amino acids) is considerably 
smaller than that reported for HTLV-1 (206 amino acids 
spliced/209 amino acids unspliced) and HTLV-2 (183 
amino acids) which argues against an exactly analogous 
protein (although the final effect may be equivalent). In 
addition to the roles ascribed to the HBZ protein, it has 
been reported that the HBZ mRNA is capable of sup-
porting proliferation [12] and is primarily retained in the 
nucleus [32], suggesting an lncRNA like function. Only a 
small portion of AS1-L is occupied by the potential ORF 
and the AS1-L\S transcript is primarily retained in the 
nucleus, again hinting at a potential lncRNA like role. 
Recently, there has been a rapid expansion of our under-
standing of the numerous roles lncRNAs play in the cell 
[33]. Many of these lncRNAs also show a predominately 
nuclear localization and are involved in transcriptional 
regulation [34]. Additionally, many transcripts previ-
ously described as lncRNAs possess small ORFs (<100 
amino acids) that do not resemble those found in well 
characterized mRNAs [35]. The situation for the BLV 
antisense transcripts appears similar. Thus, it is reason-
able to propose that one role of the BLV AS1-S/L may be 
silencing of the 5′LTR. Future work using in vitro infec-
tion with altered proviruses will be needed to firstly 
establish the precise role AS1-S/L plays in the life cycle 
of BLV and secondarily if these different roles are car-
ried out via the RNA or potential protein product. With 
this information in hand it will be interesting to compare 
and contrast the roles AS1-S/L and HBZ transcript play 
and given the tractability of the BLV model, make tar-
geted changes to the transcript and examine the effect on 
tumor development.
Looking beyond AS1-S/L there remains the enigma of 
the AS2 transcript, where at the moment the potential 
functions are even more obscure than for AS1-S/L. No 
comparable antisense transcript has been reported for 
HTLV-1 and no potential ORF is present in the transcript. 
Furthermore, the expression levels of AS2 are lower than 
that observed for AS1 (Fig. 1; Additional file 1: Fig. S2). 
Additionally, the second exon of AS2 is small (125  bp) 
creating a transcript containing just over ~400  bp of 
sequence from the BLV genome. However, the consistent 
splicing of AS2 with the host genome results in the pro-
duction of a fusion transcript containing ~400  bp from 
BLV and additional sequences from the host genome. As 
a result the AS2 transcript size and composition will dif-
fer from cell to cell depending on provirus location in the 
host genome. It has recently been reported for HTLV-1 
that antisense transcripts can also form fusion transcripts 
with the host genome [9]. Additionally we also see exten-
sive splicing between the common AS exon 1 and the 
host genome (using canonical splice acceptor sites) and 
find evidence that these fusions may play a role in leu-
kemogenesis. These observations are outlined in detail in 
Rosewick et al. submitted and point to an important role 
for antisense dependent viral/host transcripts in the biol-
ogy of deltaretroviruses.
A striking feature of many HTLV-1 and BLV proviruses 
is the large deletions frequently observed in tumors, that 
can remove over half the proviral DNA, often includ-
ing the entre 5′LTR and many vital ORFs, while always 
retaining the 3′LTR [9, 13]. These observations strongly 
indicate that HBZ plays an important role in leukemo-
genesis and a similar pattern of deletions in BLV may 
point to an analogous role for the BLV AS1-S/L. The case 
of the BLV provirus T1345 is intriguing for this reason 
as the large deletion gives us a clue about which BLV 
antisense transcripts are important in the tumor. In this 
provirus a ~4.3 kb deletion removes many essential viral 
genes but retains the BLV microRNAs [13] and continues 
to display robust antisense expression (Additional file 1: 
Fig. S5). This deletion also removes the second exon of 
AS2 and the last ~100 bp of AS1-L indicating that these 
transcripts/regions are dispensable in the tumor.
Our attempt to investigate the function of the AS1-S/L 
transcript via knock down was hampered as the YR2 and 
L267 B cell lines are refractory to transfection and require 
high levels of LNAs for unassisted uptake, making opti-
mization and long-time courses cost prohibitive. Con-
sequently, we carried out a limited number of assays and 
designed our experiment to examine if knock down of 
AS1-S/L could lead to the re-activation of viral transcrip-
tion from the 5′LTR. It has been known for some time that 
the lack of 5′LTR based expression is imposed via histone 
repressive marks and DNA methylation at the 5′LTR [15, 
16] and we hypothesized that the AS1-S/L has a role in 
maintaining this state. While we did achieve a significant 
knock down of AS1-S/L we did not see any evidence of 
transcription from the 5′LTR and based on final cell counts 
there was no apparent effect on cell viability (Additional 
file 1: Fig. S4). More prolonged or complete knock down 
may be required to produce an effect, however given the 
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large quantities of LNAs required for unassisted uptake 
this was not practical. Previous work by Colin et  al. [15] 
showed that following experimentally induced chromatin 
remodeling in the YR2 cell line there is a rapid return to a 
closed chromatin conformation. The AS-1S/L transcripts 
may play a role in this process and in order to observe any 
effect on 5′LTR based expression, AS1-S/L knock down 
must be coupled with prior relaxing of chromatin. It will 
be interesting to examine if combining LNA knock down 
of AS1 and treatment to open chromatin changes the pat-
terns of epigenetic marks observed at the BLV 5′LTR.
Conclusions
The identification of BLV antisense transcripts taken in con-
junction with the recent identification of the BLV microR-
NAs [13, 14] represent a major shift in our understanding of 
BLV pathogenesis. In contrast to the prevailing paradigm of 
a silent provirus, our work reveals that the BLV provirus is a 
prodigious producer of viral microRNAs and constitutively 
expresses antisense transcripts in all tumors examined. The 
consistent expression of these transcripts in both leukemic 
and nonmalignant clones points to a vital role in the life 
cycle of the virus and its tumorigenic potential. Additionally, 
the cleavage of the AS1-L transcript by the BLV encoded 
microRNAs and the transcriptional interference between 
the two viral RNA species suggest a shared role in the regu-
lation of BLV. While additional work is required to elucidate 
the precise roles of the BLV antisense transcripts, it is hoped 
that the greater tractability of the BLV model will provide 
key insights into HTLV-1 induced leukemia and provide a 
test bed for exploring potential treatment options.
Methods
See Additional file 1: Text S1 for full details of materials 
and methods used.
Ovine/bovine samples and cell lines
Primary ovine and bovine tumors were part of an existing 
BLV induced tumor collection maintained at −80 °C and 
described previously [13]. Asymptomatic sheep samples 
came from animals infected with the molecular clone 
pBLV344 following experimental procedures approved 
by the University of Saskatchewan Animal Care Commit-
tee, following Canadian Council on Animal Care Guide-
lines (Protocol #19940212). The cell lines YR2 and L267 
were originally derived from ovine B-cell tumors, do 
not express viral mRNAs originating in the 5′LTR [13], 
L267LtaxSN and YR2LtaxSN were produced via transduction 
with the pLTaxSn retroviral vector expressing Tax [13].
RNA sequencing
The Illumina TruSeq Total RNA stranded kit was used 
to prepare ribosomal RNA depleted libraries followed 
by sequencing on an Illumina HiSeq  2000 (2 ×  100  bp 
paired-end reads), producing approximately 60 million 
raw paired-end reads per library. For small RNAs the 
Illumina TruSeq Small RNA Library Preparation Kit was 
used followed by sequenced on an Illumina NextSeq 500 
(75 bp single reads). Reads were mapped to appropriate 
bovine UMD3.1 or ovine OAR3.1 genomes as well as 
BLV YR2 provirus genome (NCBI Accession: KT122858) 
using STAR (v2.3.1.u) and BWA (See Additional file  1: 
Text S1).
End point PCR
SuperScript III Reverse Transcriptase (Life technologies) 
was used to produce cDNA. PCR primers used are listed 
in Additional file 1: Table S4.
High‑throughput sequencing of BLV integration sites
The Bioruptor Pico (Diagenode) was used to shear 5ug of 
DNA, followed by indexing with Nextera XT indexes and 
sequencing on a Illumina MiSeq instrument. Reads were 
mapped to the host-provirus hybrid genome with BWA 
and numbers were determined for each proviral integra-
tion site using in-house R and Perl scripts.
Proviral load quantification
Proviral load was assessed with PrimeTime qPCR Assays 
(IDT) using diluted DNA from the YR2 cell line to pro-
duce a standard curve. Primers used are listed in Addi-
tional file 1: Table S4.
Identification of 5′ and 3′ ends with RACE
The GeneRacer Kit (Life Technologies) was used for 5′ 
and 3′RACE followed by high throughput sequencing 
of the resultant PCR products. Near full-length cDNA 
transcripts were also produced by PCR followed by 
either shearing with a Bioruptor Pico (Diagenode) and 
sequencing on a MiSeq instrument or sequencing of the 
full-length transcripts on a MinION instrument (Oxford 
Nanopore Technologies).
Luciferase assays
The LTR from BLV was derived from the pBLV344 plas-
mid [36], inserted into the pGL3 basic luciferase reporter 
plasmid. Constructs were transfected in triplicate with 
Lipofectamine 2000 (Life technologies) and processed 
using the Dual-Glo Luciferase Assay System (Promega). 
Statistical significance was assessed with Tukey’s multiple 
comparisons test, a p value <0.05 considered statistically 
significant.
Protein coding potential and nucleotide diversity
The Coding-Potential Assessment Tool (CPAT) [19] was 
used to assess the coding potential of the BLV antisense 
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transcripts. Sequence conservation was examined 
using sequences extracted from the bovine and ovine 
tumors sequenced as well as six genomes from NCBI 
(http://www.ncbi.nlm.nih.gov/nuccore), using the same 
approach outlined in Rosewick et al. [13].
Sub‑cellular location of BLV antisense transcripts
Cytoplasmic and nuclear fractions were produced from 
YR2 following the method outlined in Weil et  al. [37]. 
RNA sequencing was carried out as outlined above. Real 
time PCR based absolute quantification was carried 
out on a ABI Prism 7900HT Sequence Detector System 
(Applied Biosystems) using ABsolute Blue QPCR SYBR 
Green ROX Mix (Thermo Scientific) and the appropriate 
PCR product in a plasmid to produce a standard curve.
Identifying products of RISC mediated cleavage
The products of cleavage were identified with the proto-
col of Davis et al. [22] with the addition of high through-
put sequencing of the resultant PCR products on a 
Illumina MiSeq. The precise position of cleavage was 
determined via mapping to the BLV provirus genome 
with BWA and a custom BASH script.
Deleting and inverting the BLV microRNAs
The altered proviruses used the wild type molecu-
lar clone pBLV344 [36] as the starting material. In the 
deleted provirus 554 bp containing the BLV microRNAs 
was removed and replaced with the MluI restriction 
site. In the inverted provirus the BLV microRNAs were 
reinserted into this MluI restriction site in an inverted 
orientation. The constructs were transfected into HeLa 
cells with Lipofectamine 2000 (Life technologies) and 
real time PCR and 3′RACE carried out as described 
above.
Antisense knock down with locked nucleic acid antisense 
oligos (LNAs)
The antisense transcript was targeted with a mix of three 
locked nucleic acid antisense oligos (Exiqon) introduced 
via unassisted uptake [38] in duplicate for a half million 
YR2 and L267 cells. Final concentrations of 5 and 10 μM 
were tested, as well as the LNA longRNA GapmeR Nega-
tive control A (Exiqon), at a final concentration of 10 μM 
and a mock treatment of H2O. Real time PCR was carried 
out as outlined above and statistical significance assessed 
via a Kruskal–Wallis test and Dunn’s multiple compari-
sons test, p values of ≤0.05 were considered to be statisti-
cally significant.
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